Successful treatment of type II pityriasis rubra pilaris with secukinumab
Authors:
Open Access
- 1 November 2016
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 2 (6) , 462-464
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra PilarisJAMA Dermatology, 2016
- Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor ApremilastJAMA Dermatology, 2016
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2015
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialJournal of the American Academy of Dermatology, 2015
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsNew England Journal of Medicine, 2014
- Effectiveness of Infliximab in Pityriasis Rubra Pilaris Is Associated with Pro-Inflammatory Cytokine InhibitionDermatology, 2013
- A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF‐antagonistsJournal of the European Academy of Dermatology and Venereology, 2012
- Treatment of pityriasis rubra pilaris with ustekinumabBritish Journal of Dermatology, 2010